Lexaria Bioscience Corp. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Discontinued Operations (Details 1)

Discontinued Operations (Details 1) - USD ($)	12 Months Ended
Discontinued Operations (Details 1) - USD ($)	Aug. 31, 2021	Aug. 31, 2020
Discontinued Operations
Revenue	$ 3,000	$ 69,750
Operating Expenses	(25,000)	(5,566)
Net income	$ (22,000)	$ 64,184

- Definition

Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details